Press Releases

Press Release 3 

Haoma Medica Announces Plenary Presentation for NaQuinate, a Potential Novel Treatment for Osteoporosis, at ASBMR 2020 Annual Meeting

 

London, UK, 11 September 2020 - Haoma Medica announced a presentation made today at the 2020 American Society for Bone and Mineral Research:

Dr Andrew Pitsillides, Professor of Skeletal Dynamics at the Royal Veterinary College, London presented: 'NaQuinate: A Drug that Selectively Synergizes with Mechanical Loading Stimuli In Vivo to Generate Greater Cortical Bone Mass and Architectural Modifications’.


Previous studies have shown NaQuinate, a naphthoquinone carboxylic acid, to protect against reduction in bone quality and quantity occurring in response to ovariectomy in rat and mouse models. In the data presented today using an applied mechanical mouse loading model, NaQuinate synergized the body’s normal response to loading (a surrogate for greater weight-bearing exercise) to generate significant increases in cortical bone mass (increased cross sectional area, reductions in cortical porosity) and J-score (predictor of bone strength) compared to loading alone; the combined effect of loading and NaQuinate was much greater than additive. The bone studied here was the tibia in the leg, one of the largest bones in the body and where cortical bone is the core component.

 

‘There are 3 ways to maintain bone quality and strength to resist fracture - stop bone loss, build mass and enhance the topographical changes to optimize and enhance weight-bearing roles. It may be that NaQuinate can achieve a balance of all three to treat osteoporosis and better maintain healthy aging,’ said Professor Andrew Pitsillides, presenting author.

 

NaQuinate as a treatment for post-menopausal women with osteoporosis, is an investigational product, currently in Phase I clinical trials and its safety and efficacy have not been established.

 

About Osteoporosis and Cortical Bone


Cortical bone is the dense outer shell of bone that forms a protective layer around the internal cavity. It is imperative to body structure and weight bearing because of its high resistance to bending and twisting.

 

Osteoporosis is a silent disease often not presenting with any symptoms until a fracture occurs. It thus remains an underdiagnosed and undertreated disease.

 

Osteoporosis results in bone loss and changes in bone quality and strength that occurs through the normal aging process leading to fragile bones. Fragile bones lead to fractures, which progresses into a downward spiral of disability, loss of independence and increased mortality with considerable social and economic burden. Fragility fractures are therefore a major obstacle to healthy aging. Worldwide there is a fragility fracture every 3 seconds.

 

According to the National Osteoporosis Foundation about 54 million Americans have osteoporosis with studies suggesting one in two women and one in four men aged 50 and older will have a fragility fracture (or low impact fracture often occurring from a minor bump or fall from standing height) within their life.

 

About Haoma Medica

Haoma Medica Ltd is a clinical-stage biotechnology company focused on the development of therapeutics to maintain bone and vascular health. For more information, please visit www.haomamedica.com

 

Investor Relations Contact

Name: Carmen Greco                                              

e-mail: carmen.greco@haomamedica.com          

Phone: +44(0)207 629 1954          

Press Release 2
RVC researcher presents poster on a potentially exciting new treatment for skeletal disorders

 

London, UK, 10 September 2020 - Dr Andrew Pitsillides, Professor of Skeletal Dynamics at the Royal Veterinary College (RVC) has today presented a poster at the American Society of Bone and Mineral Research (ASBMR) highlighting a potential new treatment for skeletal disorders such as osteoporosis.

Osteoporosis affects over 3 million people in the UK and more than 500,000 people receive hospital treatment for bones that break after falling from standing height or less every year due to the condition. The condition also creates a significant social and economic burden, with fractures often leading to a downward spiral of disability, loss of independence and increased mortality more...

Press Release 1
Haoma Medica to Present Scientific Data on NaQuinate, a Potential New Treatment for Osteoporosis, at the Upcoming ASBMR 2020 Annual Meeting

 

London, UK, 10 September 2020 - Haoma Medica announced today that it will present three scientific posters on NaQuinate at the upcoming American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting, which this year takes place as a virtual event from 11-15 September.

NaQuinate, a naphthoquinone carboxylic acid, is being developed as a novel orally administered therapeutic for osteoporosis. ‘’Haoma Medica is dedicated to investigating new ways to treat osteoporosis and maintain healthy aging and we look forward to sharing new pre-clinical data for NaQuinate at this key meeting with bone health experts’’ said Prof Stephen Hodges, Haoma Medica’s Chief Scientific Officer more...

Contact Information

Office Phone  (+44) 0207 629 1954

LBIC Phone    (+44) 0189 526 5540

Emails

info@haomamedica.com

stephen.hodges@haomamedica.com (CSO)

stephen.deacon@haomamedica.com (CEO)

carmen.greco@haomamedica.com (CFO)

cenk.oguz@haomamedica.com (CMO)

Mailing Address

Haoma Medica Ltd.

c/o London BioScience Innovation Centre

2 Royal College Street 

London, England

United Kingdom

NW1 0NH

LinkedIn Haoma Medica

Company Registration GB No. 06784000